Introduction: Since the launch of the Global Polio Eradication Initiative (GPEI) in 1988, there has been a tremendous progress in the reduction of cases of poliomyelitis. The world is on the verge of achieving global polio eradication and in May 2013, the 66th World Health Assembly endorsed the Polio Eradication and Endgame Strategic Plan (PEESP) 2013-2018. The plan provides a timeline for the completion of the GPEI by eliminating all paralytic polio due to both wild and vaccine-related polioviruses.

Methods: We reviewed how GPEI supported communicable disease surveillance in seven of the eight countries that were documented as part of World Health Organization African Region best practices documentation. Data from WHO African region was also reviewed to analyze the performance of measles cases based surveillance.

Results: All 7 countries (100%) which responded had integrated communicable diseases surveillance core functions with AFP surveillance. The difference is on the number of diseases included based on epidemiology of diseases in a particular country. The results showed that the polio eradication infrastructure has supported and improved the implementation of surveillance of other priority communicable diseases under integrated diseases surveillance and response strategy.

Conclusion: As we approach polio eradication, polio-eradication initiative staff, financial resources, and infrastructure can be used as one strategy to build IDSR in Africa. As we are now focusing on measles and rubella elimination by the year 2020, other disease-specific programs having similar goals of eradicating and eliminating diseases like malaria, might consider investing in general infectious disease surveillance following the polio example.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.vaccine.2016.05.060DOI Listing

Publication Analysis

Top Keywords

polio eradication
24
communicable diseases
12
diseases surveillance
12
african region
12
polio
8
eradication initiative
8
global polio
8
disease surveillance
8
diseases
7
surveillance
7

Similar Publications

WPV1 resurgence in Pakistan: Endangering the global polio eradication goal.

Infect Dis Now

January 2025

Molecular Virology Lab, Department of Biotechnology, Faculty of Biological Sciences, Quaid-i-Azam University, 45320 Islamabad, Pakistan. Electronic address:

View Article and Find Full Text PDF

Beyond Poliomyelitis: A 21-Year Study of Non-Polio Enterovirus Genotyping and Its Relevance in Acute Flaccid Paralysis in São Paulo, Brazil.

Viruses

December 2024

Divisão de Doenças de Transmissão Hídrica e Alimentar, Centro de Vigilância Epidemiológica "Prof. Alexandre Vranjac", Secretaria de Estado da Saúde de São Paulo, Sao Paulo 01246-900, Brazil.

In the context of the near-global eradication of wild poliovirus, the significance of non-polio enteroviruses (NPEVs) in causing acute flaccid paralysis (AFP) and their impact on public health has gained increased attention. This research, conducted from 2001 to 2021, examined stool samples from 1597 children under 15 years in São Paulo, Brazil, through the AFP/Poliomyelitis Surveillance Program, detecting NPEVs in 6.9% of cases.

View Article and Find Full Text PDF

As we commemorate 50 years of the Expanded Programme on Immunization (EPI), the global mission to eradicate polio stands at a critical juncture. While remarkable progress has been made over the past decades, ensuring a steady supply of polio vaccines remains a significant challenge that could undermine these achievements. This manuscript aims to address the complexities of polio vaccine security within the context of the Immunization Agenda 2030 (IA2030) and the Global Polio Eradication Strategy 2022-2029, proposing actionable strategies to strengthen the vaccine supply.

View Article and Find Full Text PDF

Polio Epidemiology: Strategies and Challenges for Polio Eradication Post the COVID-19 Pandemic.

Vaccines (Basel)

November 2024

Sanofi Vaccines Medical, 14 Espace Henri Vallee, 69007 Lyon, France.

The Global Polio Eradication Initiative (GPEI), launched in 1988, has successfully reduced wild poliovirus (WPV) cases by over 99.9%, with WPV type 2 and WPV3 declared eradicated in 2015 and 2019, respectively. However, as of 2024, WPV1 remains endemic in Afghanistan and Pakistan.

View Article and Find Full Text PDF

Although wild poliovirus type 2 has been eradicated, the prolonged transmission of the live- attenuated virus contained in the type-2 oral polio vaccine (OPV2) in under-immunized populations has led to the emergence of circulating vaccine-derived poliovirus type 2 (cVDPV2). The novel OPV2 (nOPV2) was designed to be more genetically stable and reduce the chance of cVDPV2 emergence while retaining comparable immunogenicity to the Sabin monovalent OPV2 (mOPV2). This study aimed to estimate the relative reduction in the emergence risk due to the use of nOPV2 instead of mOPV2.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!